Table 5 Bleeding cases by dabigatran dose and each factor

Very low-dose (75 mg twice daily)

3

23

1.50 [0.44–5.16], (0.520)

Age, years

74.0 ± 9.0

70.9 ± 11.0

1.03 [1.00–1.06], (0.036*)

Gender, female

19

225

1.07 [0.60–1.90], (0.808)

Creatinine clearance: Ccr (mL/min)

61.6 ± 29.4

69.4 ± 24.9

0.99 [0.97–1.01], (0.038*)

History of bleeding

9

70

1.53 [0.72–3.27], (0.264)

New users

19

335

0.46 [0.26–0.82], (0.007*)

Change from warfarin

26

206

1.81 [1.05–3.12], (0.034*)

C: Congestive heart failure

12

126

1.01 [0.51–1.96], (0.987)

H: Hypertension

38

388

0.76 [0.42–1.39], (0.376)

A: Aged 75 or older

33

261

1.78 [1.02–3.10], (0.043*)

D: Diabetes Mellitus

9

131

0.67 [0.32–1.39], (0.282)

S: Stroke/TIA (2 points)

24

161

2.00 [1.15–3.51], (0.015*)

CHADS2 score

2.44 ± 1.34

1.90 ± 1.34

1.33 [1.09–1.61], (0.005*)

With antiplatelet agents

17

112

2.02 [1.10–3.69], (0.022*)